Shares of AC Immune SA (NASDAQ:ACIU) have been assigned an average recommendation of “Hold” from the six research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $13.00.

Several research firms have recently issued reports on ACIU. BidaskClub cut AC Immune from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 20th. ValuEngine cut AC Immune from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 9th. Finally, Zacks Investment Research cut AC Immune from a “buy” rating to a “hold” rating in a research note on Monday, April 8th.

NASDAQ:ACIU opened at $5.01 on Friday. AC Immune has a 1 year low of $3.25 and a 1 year high of $17.40. The firm has a market capitalization of $341.86 million, a PE ratio of -6.11 and a beta of -0.16. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.01.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Wednesday, May 15th. The company reported $0.84 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.36). AC Immune had a return on equity of 12.17% and a net margin of 29.66%. The business had revenue of $75.28 million during the quarter, compared to the consensus estimate of $106.81 million. As a group, sell-side analysts predict that AC Immune will post 0.69 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in ACIU. BVF Inc. IL lifted its holdings in shares of AC Immune by 234.3% in the first quarter. BVF Inc. IL now owns 7,455,534 shares of the company’s stock valued at $37,650,000 after buying an additional 5,225,507 shares during the period. Prosight Management LP acquired a new stake in shares of AC Immune in the first quarter valued at $3,588,000. BlackRock Inc. acquired a new stake in shares of AC Immune in the fourth quarter valued at $6,092,000. FMR LLC lifted its holdings in shares of AC Immune by 7.7% in the fourth quarter. FMR LLC now owns 5,612,759 shares of the company’s stock valued at $53,039,000 after buying an additional 403,086 shares during the period. Finally, Artisan Partners Limited Partnership acquired a new stake in shares of AC Immune in the first quarter valued at $903,000. 26.54% of the stock is owned by institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Featured Story: What is required to own or exchange cryptocurrency?

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.